Oncolytics Biotech Inc (ONCY)

$1.01 0.00 (N/A)
Market Cap 101.37M
Revenue (ttm) 0.00
Net Income (ttm) -23.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 481,200
Avg Vol 1,154,158
Day's Range N/A - N/A
Shares Out 100.36M
Stochastic %K 69%
Beta 1.09
Analysts Strong Sell
Price Target $4.12

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology
Sector: Healthcare
Phone: 403-670-7377
Fax: 403-283-0858
Address:
322 11th Avenue SW, Suite 804, Calgary, Canada
GoPatzGo123
GoPatzGo123 Aug. 24 at 1:42 PM
$ONCY anyone know when this company will cure cancer?..... Asking for a friend
1 · Reply
FoxM07
FoxM07 Aug. 23 at 1:14 PM
$ONCY what to make of this new sedi filing? What a ridiculously generous granting of options. What have any of them done to warrant this? They certainly haven't addressed shareholder value.
1 · Reply
AI1234
AI1234 Aug. 22 at 5:02 PM
$ONCY Record highs on the U.S. exchanges with stocks up significantly across the board, well almost all stocks….come-on Jared, sell the company and unlock shareholder value….
1 · Reply
FoxM07
FoxM07 Aug. 22 at 1:51 PM
$ONCY wow, 4000 vol. on the TSX!!! The shorts are running for the hills!!!
1 · Reply
stockinfocuz_
stockinfocuz_ Aug. 22 at 1:12 PM
$PHRRF Strong buy TA on @barchart #tradingview - Trending spot. $ONCY $MSOS
0 · Reply
saxy4u
saxy4u Aug. 21 at 4:19 PM
$ONCY Who remembers Dr.Vile and his 100% success rate in mouse model in Glio and Melanoma transformation cold to hot tumours?
2 · Reply
saxy4u
saxy4u Aug. 21 at 2:27 PM
$ONCY here goes the switch over and cover today!! Thank god 100% Nas tomorrow!!!
1 · Reply
saxy4u
saxy4u Aug. 20 at 10:46 PM
$ONCY my thoughts!
1 · Reply
saxy4u
saxy4u Aug. 20 at 4:24 PM
$ONCY I wonder if the shorts in the Canadian side are panicking yet? They will have to cover before Friday, price will raise 20% by Friday!!!
2 · Reply
macjohn1
macjohn1 Aug. 20 at 4:18 PM
$ONCY - Opportunity
0 · Reply
Latest News on ONCY
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 11, 2025, 4:55 PM EDT - 13 days ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:05 AM EDT - 16 days ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 8, 2025, 9:00 AM EDT - 16 days ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Aug 5, 2025, 8:30 AM EDT - 19 days ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 29, 2025, 8:30 AM EDT - 26 days ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 23, 2025, 9:39 AM EDT - 4 weeks ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 3:32 PM EDT - 4 weeks ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 16, 2025, 8:30 AM EDT - 5 weeks ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 10, 2025, 8:30 AM EDT - 6 weeks ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jul 8, 2025, 8:30 AM EDT - 6 weeks ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 30, 2025, 7:00 AM EDT - 7 weeks ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Jun 11, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025, 7:00 AM EDT - 3 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:21 PM EDT - 3 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025, 4:01 PM EDT - 3 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025, 7:00 AM EDT - 3 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 24, 2025, 7:00 AM EDT - 4 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 6:09 PM EDT - 4 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Apr 10, 2025, 7:00 AM EDT - 4 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 11:11 AM EST - 6 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Mar 7, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 25, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 19, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 18, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 14, 2025, 5:15 PM EST - 6 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Feb 7, 2025, 9:24 PM EST - 7 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 22, 2025, 7:00 AM EST - 7 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Jan 15, 2025, 7:02 AM EST - 7 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 23, 2024, 7:00 AM EST - 8 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 18, 2024, 7:00 AM EST - 8 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Dec 3, 2024, 7:00 AM EST - 9 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:01 PM EST - 10 months ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 12, 2024, 7:00 AM EST - 10 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Nov 11, 2024, 7:00 AM EST - 10 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Oct 4, 2024, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:55 PM EDT - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Jun 20, 2024, 7:26 AM EDT - 1 year ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 15, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:48 PM EDT - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

May 9, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

GoPatzGo123
GoPatzGo123 Aug. 24 at 1:42 PM
$ONCY anyone know when this company will cure cancer?..... Asking for a friend
1 · Reply
FoxM07
FoxM07 Aug. 23 at 1:14 PM
$ONCY what to make of this new sedi filing? What a ridiculously generous granting of options. What have any of them done to warrant this? They certainly haven't addressed shareholder value.
1 · Reply
AI1234
AI1234 Aug. 22 at 5:02 PM
$ONCY Record highs on the U.S. exchanges with stocks up significantly across the board, well almost all stocks….come-on Jared, sell the company and unlock shareholder value….
1 · Reply
FoxM07
FoxM07 Aug. 22 at 1:51 PM
$ONCY wow, 4000 vol. on the TSX!!! The shorts are running for the hills!!!
1 · Reply
stockinfocuz_
stockinfocuz_ Aug. 22 at 1:12 PM
$PHRRF Strong buy TA on @barchart #tradingview - Trending spot. $ONCY $MSOS
0 · Reply
saxy4u
saxy4u Aug. 21 at 4:19 PM
$ONCY Who remembers Dr.Vile and his 100% success rate in mouse model in Glio and Melanoma transformation cold to hot tumours?
2 · Reply
saxy4u
saxy4u Aug. 21 at 2:27 PM
$ONCY here goes the switch over and cover today!! Thank god 100% Nas tomorrow!!!
1 · Reply
saxy4u
saxy4u Aug. 20 at 10:46 PM
$ONCY my thoughts!
1 · Reply
saxy4u
saxy4u Aug. 20 at 4:24 PM
$ONCY I wonder if the shorts in the Canadian side are panicking yet? They will have to cover before Friday, price will raise 20% by Friday!!!
2 · Reply
macjohn1
macjohn1 Aug. 20 at 4:18 PM
$ONCY - Opportunity
0 · Reply
cryingangel
cryingangel Aug. 20 at 3:03 PM
$ONCY 559 bought. New here. Let s go
0 · Reply
saxy4u
saxy4u Aug. 19 at 8:24 PM
$ONCY ok Peeps! Loaded backup again! Let’s see the business acumen of the newbies! $20-$40 buyout price $2-4bill buyout. Once the new patents are declared and the FDA registration Guidance is done, you will see either buyout or partnership by EOY. This will run like it did before! Still think they may do a 10-1 share reverse to get make it easier for new ownership . 10 mill shares is easier to play with then 100mill. No more ATM short selling to deal with. All the best to the Longs. Not worth what it was once but with 10years new patents. 100% US traded.
2 · Reply
hashhampton
hashhampton Aug. 19 at 2:12 PM
$VKTX I'm in! Thanks for the cheapies! See you at $80. My my my, what a wonderful day! $ONCY
0 · Reply
hashhampton
hashhampton Aug. 19 at 1:12 PM
$VKTX Load up pre-market or wait to the open if you must. This is the steal of the day. This discount won't last long. When opportunities present themselves like this, take advantage people! $BTC.X $ONCY $LLY
1 · Reply
stockinfocuz_
stockinfocuz_ Aug. 19 at 12:18 PM
$ONCY Chart
0 · Reply
CaseyLe
CaseyLe Aug. 18 at 1:46 PM
$ONCY purchasing
1 · Reply
stockinfocuz_
stockinfocuz_ Aug. 18 at 12:30 PM
$ONCY Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders SAN DIEGO, Aug. 11, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. https://finance.yahoo.com/news/oncolytics-biotech-announces-voting-results-205500517.html
0 · Reply
ostrich
ostrich Aug. 18 at 12:43 AM
$ONCY $RMSG $DXF $OVID $AABB Fire Chart as Well!
1 · Reply
ostrich
ostrich Aug. 18 at 12:42 AM
$ONCY $RMSG $DXF $OVID $AABB Yes Gold is Huge in Medical Resources and A.I Resources! Graphene deal added!
0 · Reply
ostrich
ostrich Aug. 18 at 12:41 AM
$ONCY $RMSG $DXF $OVID fire opportunities both sides $AABB
0 · Reply
SupremeImage
SupremeImage Aug. 17 at 9:31 PM
TGL Don't miss this beaten down crypto treasury stock. Looks like chart is ready to explode, plus expecting more incoming catalyst. - Treasure Global Launches US$100 Million Digital Asset Treasury Strategy to Power Next-Gen Consumer Intelligence Platform. $ONCY $RMSG $DXF $OVID
0 · Reply
exwallstcfo
exwallstcfo Aug. 15 at 9:32 PM
Action in biotechs on a Friday nite .....VERY RARE !!! $XBI above the 200 day. .... huge development The small nano caps catching a bid $ONCY $TOVX I still believe 2nd half of year ..... still very much in play !!
1 · Reply